Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT01208649 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of the medication Exenatide (Byetta®) on liver function in adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 13 people

Who can join Ages 18–75 · all sexes Healthy volunteers accepted.

Timeline Started 2008-07 · est. completion 2010-09

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT01208649 ↗

Description as written by the study sponsor.

The primary objective is to test the hypothesis that 24 weeks of treatment with exenatide will improve the histological acitvity of NASH (steatosis,necroinflammation, ballooning), summarized in the recently introduced NASH-score in patients with normal, impaired or diabetic glucose tolerance compared to dietary guidance alone.

Treatments tested

Exenatide Drug

Exenatide; 48 weeks 10 microg injection s.c., twice daily, before the morning and evening meal with a four week wash-in phase with 5 microg injection s.c.twice daily

Main thing measured	histological activity of NASH (steatosis, necroinflammation, ballooning)
Sponsor	Ruhr University of Bochum
Conditions studied	Nonalcoholic Fatty Liver Disease
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01208649 ↗